Investors Eligible for Share of $175M Becton Fair Fund

The settlement stems from a December 2024 SEC order finding that Becton, Dickinson and Company failed to disclose critical risks associated with its Alaris infusion device. The company’s stock price dropped approximately 12% on February 6, 2020, after management announced a need for new FDA clearance and a halt in sales, revealing that previous financial guidance had been based on incomplete risk assessments. While the company did not admit or deny the findings, it consented to the civil penalty and the creation of a Fair Fund under the Sarbanes-Oxley Act to reimburse affected shareholders.

To participate, claimants must submit documentation to JND Legal Administration by the December 13, 2026, deadline. Claim forms and detailed instructions are available at www.BectonFairFund.com. Brokers and nominees holding records for beneficial owners are required to provide notification of this claims process within 14 days of receiving notice packets. For additional assistance, investors may contact the administrator at (866) 910-1105.